Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer
Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer
复制标题
DOI：
10.1002/ijc.25077
复制
发表时间：
2010-08-01
影响因子：
6.4
通讯作者：
Kulikowski, Marek
中科院分区：
文献类型：
--
作者：
Dobrzycka, Bozena;Terlikowski, Slawomir J.;Kulikowski, Marek
本研究旨在探讨循环游离DNA（CFDNA）、p53抗体（p53-Ab）和KRAS基因突变在子宫内膜癌（EC）发生发展中的意义。共有109例EC患者（87例I型患者和22例II型患者）参加了本研究。采用PCR-RFPL方法富集KRAS突变和CFDNA。ELISA法检测血浆p53-Ab。免疫组化（IHC）检测P53蛋白的组织表达。KRAS突变的频率在I型EC的2级中特别高。CFDNA在早期II型食管癌患者中检出率较高，但级别较低。值得注意的是，p53-Ab阳性率在较高级别的I型肿瘤中增加。在I型肿瘤的晚期阶段，发现具有p53-Ab的病例数的显著差异。KRAS和p53-Ab的频率仅在I型EC中与肿瘤分期相关。血浆CFDNA和p53-Ab为开发用于EC II型诊断的程序提供了机会。CFDNA和p53-Ab相关的肿瘤细胞与II型肿瘤的相关性表明，CFDNA和p53-Ab可能作为预测预后的标志物，并提供了个体化治疗方案的可能性。
This study was conducted to evaluate the significance of circulating free DNA (CFDNA), p53 antibody (p53-Ab) and mutations of KRAS gene in the development of endometrial cancer (EC). A total of 109 patients with EC (87 patients with Type I and 22 patients with Type II) took part in this study. KRAS mutations and CFDNA were detected by means of the PCR-RFLP and enriched by the PCR-RFPL method. ELISA was used to analyze plasma p53-Ab. Tissue expression of P53 protein was evaluated immunohistochemically (IHC). The frequency of KRAS mutations was especially high in Grade 2 of Type I EC. CFDNA was frequently detected in patients with early stage of Type II EC at a low level of grade. It is noteworthy that the p53-Ab positive rate increased in the higher grade of Type I tumors. A significant difference in the number of cases with the p53-Ab was found in the advanced stage of Type I tumors. The frequency of KRAS and p53-Ab correlates with tumor stage only in the Type I EC. Plasma CFDNA and p53-Ab offer a chance to develop a procedure for EC Type II diagnosis. The association between tumor cells related to CFDNA and p53-Ab with Type II tumor suggests that it might potentially serve as a marker in predicting the prognosis and offers a possibility to individualize treatment regimen.